CCI greenlights Mankind Pharma's Rs 13,630 crore takeover of Bharat Serums

3 Oct 2024 , 11:02 AM

The Competition Commission of India (CCI) has approved Mankind Pharma’s acquisition of Bharat Serums and Vaccines for ₹13,630 crore.

The agency stated in a statement on Wednesday that “the proposed transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines by Mankind Pharma.” Mankind announced in July that it would purchase the whole stake in Bharat Serums and Vaccines from private equity firm Advent International.

Mankind manufactures and markets a wide range of pharmaceutical finished dosage formulations, as well as various consumer healthcare items. Bharat Serums and Vaccines manufactures and markets final dose formulations, as well as active medicinal components.

According to the company, this strategic move positions Mankind Pharma as a market leader in the Indian women’s health and fertility drug market, as well as providing access to other high-entry barrier products in critical care with established complex R&D tech platforms.

For feedback and suggestions, write to us at [e-mail]